The future of colorectal cancer: Implications of screening

Gut

Volumn 62, Issue 10, 2013, Pages 1387-1389

  Neerincx, Maarten ^a   Buffart, Tineke E ^a   Mulder, Chris J J ^a   Meijer, Gerrit A ^a   Verheul, Henk M W ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; MICRORNA; TUMOR MARKER;

ARTICLE; CANCER SCREENING; CANCER STAGING; COLON CARCINOGENESIS; COLONOSCOPY; COLORECTAL CANCER; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC MUCOSAL RESECTION; ENDOSCOPIC SUBMUCOSAL DISSECTION; HUMAN; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; MINIMALLY INVASIVE SURGERY; NATURAL ORIFICE TRANSLUMINAL ENDOSCOPIC SURGERY; OCCULT BLOOD TEST; OPTICAL COHERENCE TOMOGRAPHY; PATIENT SELECTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

CHEMOTHERAPY; COLORECTAL CANCER; COLORECTAL CANCER SCREENING; MOLECULAR ONCOLOGY; THERAPEUTIC ENDOSCOPY;

COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; EARLY DETECTION OF CANCER; HUMANS; LYMPHATIC METASTASIS; PATIENT SELECTION; SURGICAL PROCEDURES, MINIMALLY INVASIVE;

EID: 84884282709     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2013-305023     Document Type: Article

References (33)

1. Signaleringscommissie Kanker. Kanker in Nederland tot 2020. Trends en Prognoses. Amsterdam: Dutch Cancer Society, 2011.
2. Wilschut JA, Hol L, Dekker E, et al. Cost-Effectiveness analysis of a quantitative immunochemical test for colorectal cancer screening. Gastroenterology 2011;141:1648-55.
3. Steele RJ, McClements P, Watling C, et al. Interval cancers in a FOBT-Based colorectal cancer population screening programme: Implications for stage, gender and tumour site. Gut 2012;61:576-81.
4. Van Rossum LG, Van Rijn AF, Van Munster IP, et al. Earlier stages of colorectal cancer detected with immunochemical faecal occult blood tests. Neth J Med 2009;67:182-6.
5. Health Council of the Netherlands. Bevolkingsonderzoek naar darmkanker. Den Haag: Health Council of the Netherlands, 2009.
6. Oort FA, Terhaar Sive Droste JS, Van Der Hulst RW, et al. Colonoscopy-controlled intra-individual comparisons to screen relevant neoplasia: faecal immunochemical test vs. guaiac-Based faecal occult blood test. Aliment Pharmacol Ther 2010;31: 432-9.
7. Hoff G, Grotmol T, Skovlund E, et al. Risk of colorectal cancer seven years after flexible sigmoidoscopy screening: Randomised controlled trial. BMJ 2009;338:b1846.
8. Lansdorp-Vogelaar I, Van BM, Zauber AG, et al. Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening. J Natl Cancer Inst 2009;101:1412-22.
9. Levin TR, Jamieson L, Burley DA, et al. Organized colorectal cancer screening in integrated health care systems. Epidemiol Rev 2011;33:101-10.
10. Holt BA, Bourke MJ. Wide field endoscopic resection for advanced colonic mucosal neoplasia: Current status and future directions. Clin Gastroenterol Hepatol 2012;10:969-79.
11. Moss A, Bourke MJ, Tran K, et al. Lesion isolation by circumferential submucosal incision prior to endoscopic mucosal resection (CSI-EMR) substantially improves en bloc resection rates for 40-Mm colonic lesions. Endoscopy 2010;42:400-4.
12. Kaltenbach T, Saito Y, Tada K, et al. Incidence of lymph node metastasis from sessile or nonpolypoid early colon cancer: Stratified criteria to decide when to operate or when to watch [abstract]. Gastrointest Endosc 2011;73(Suppl 1):AB291-92.
13. Vakoc BJ, Fukumura D, Jain RK, et al. Cancer imaging by optical coherence tomography: Preclinical progress and clinical potential. Nat Rev Cancer 2012;12:363-8.
14. Suter MJ, Vakoc BJ, Yachimski PS, et al. Comprehensive microscopy of the esophagus in human patients with optical frequency domain imaging. Gastrointest Endosc 2008;68:745-53.
15. Lue N, Ganta S, Hammer DX, et al. Preliminary evaluation of a nanotechnology-Based approach for the more effective diagnosis of colon cancers. Nanomedicine 2010;5:1467-79.
16. Allegra CJ, Yothers G, O?Connell MJ, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: Results of NSABP protocol C-08. J Clin Oncol 2011;29:11-16.
17. Watanabe T, Wu TT, Catalano PJ, et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001;344: 1196-206. (Pubitemid 32319494)
18. Roth AD, Delorenzi M, Tejpar S, et al. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. J Natl Cancer Inst 2012;104:1635-46.
19. Shinbrot E, Nils Weinhold N, Schultz N, et al. Polymerase epsilon (POLE) mutations and mutator phenotypes in colorectal and endometrial tumors [abstract]. Proceedings of the 104th Annual Meeting of the American Association for Cancer Research 2013 Apr 6-10; 2013, Abstract nr 1114.
20. Dienstmann R, Vilar E, Tabernero J. Molecular predictors of response to chemotherapy in colorectal cancer. Cancer J 2011;17:114-26.
21. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007;318:1108-13. (Pubitemid 350134889)
22. Rahbari NN, Bork U, Motschall E, et al. Molecular detection of tumor cells in regional lymph nodes is associated with disease recurrence and poor survival in node-Negative colorectal cancer: A systematic review and meta-Analysis. J Clin Oncol 2012;30:60-70.
23. Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008;14:985-90.
24. Agesen TH, Sveen A, Merok MA, et al. Colo Guide Ex: A robust gene classifier specific for stage II colorectal cancer prognosis. Gut 2012;61:1560-7.
25. Brosens RP, Belt EJ, Haan JC, et al. Deletion of chromosome 4q predicts outcome in stage II colon cancer patients. Cell Oncol 2011;34:215-23.
26. Schepeler T, Reinert JT, Ostenfeld MS, et al. Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res 2008;68:6416-24.
27. Weissmann-Brenner A, Kushnir M, Lithwick YG, et al. Tumor microRNA-29a expression and the risk of recurrence in stage II colon cancer. Int J Oncol 2012;40:2097-103.
28. Ma Y, Zhang P, Wang F, et al. miR-150 as a potential biomarker associated with prognosis and therapeutic outcome in colorectal cancer. Gut 2012;61:1447-53.
29. Wang S, Wang L, Bayaxi N, et al. A microRNA panel to discriminate carcinomas from high-Grade intraepithelial neoplasms in colonoscopy biopsy tissue. Gut 2013;62:280-9.
30. Al-Nedawi K, Meehan B, Rak J. Microvesicles: Messengers and mediators of tumor progression. Cell Cycle 2009;8:2014-18.
31. Pegtel DM, Cosmopoulos K, Thorley-Lawson DA, et al. Functional delivery of viral miRNAs via exosomes. Proc Natl Acad Sci USA 2010;107:6328-33.
32. Bosch LJ, Oort FA, Neerincx M, et al. DNA methylation of phosphatase and actin regulator 3 detects colorectal cancer in stool and complements FIT. Cancer Prev Res 2012;5:464-72.
33. Ahlquist DA, Zou H, Domanico M, et al. Next-Generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterology 2012;142:248-56.